About adicet bio inc - ACET
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
ACET At a Glance
Adicet Bio, Inc.
131 Dartmouth Street
Boston, Massachusetts 02116
| Phone | 1-650-503-9095 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -116,803,000.00 | |
| Sector | Health Technology | Employees | 102 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ACET Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.507 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.741 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.172 |
ACET Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,145,127.451 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ACET Liquidity
| Current Ratio | 7.474 |
| Quick Ratio | 7.474 |
| Cash Ratio | 7.363 |
ACET Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -56.622 |
| Return on Equity | -67.552 |
| Return on Total Capital | -67.148 |
| Return on Invested Capital | -62.886 |
ACET Capital Structure
| Total Debt to Total Equity | 9.257 |
| Total Debt to Total Capital | 8.473 |
| Total Debt to Total Assets | 7.662 |
| Long-Term Debt to Equity | 7.256 |
| Long-Term Debt to Total Capital | 6.641 |